%0 Journal Article
%A Livingstone, E.
%A Gogas, H. J.
%A Kandolf, L.
%A Meier, F.
%A Eigentler, T. K.
%A Ziemer, M.
%A Terheyden, P.
%A Gesierich, A.
%A Herbst, R. A.
%A Kähler, K. C.
%A Ziogas, D. C.
%A Mijušković, Ž
%A Garzarolli, M.
%A Garbe, C.
%A Roesch, A.
%A Ugurel, S.
%A Gutzmer, R.
%A Gaudy-Marqueste, C.
%A Kiecker, F.
%A Utikal, J.
%A Hartmann, M.
%A Miethe, S.
%A Eckhardt, S.
%A Zimmer, Laura
%A Schadendorf, D.
%T Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.
%J ESMO open
%V 10
%N 5
%@ 2059-7029
%C [London]
%I Elsevier
%M DKFZ-2025-00949
%P 105053
%D 2025
%X Optimal sequencing of immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) in BRAFV600-positive advanced melanoma should achieve rapid tumour control and durable progression-free survival (PFS), translating into prolonged overall survival (OS).The 1 : 1 randomised phase II ImmunoCobiVem trial compared-after a 3-month run-in phase with vemurafenib (VEM, 960 mg twice daily) and cobimetinib (COB, 60 mg daily days 21-28, q4w)-continuous VEM + COB until disease progression (PD1) and second-line atezolizumab (ATEZO, 1200 mg, q3w) in arm A versus early switch to ATEZO after run-in, followed by crossover to VEM + COB at PD1, in arm B. PFS from the start of run-in until PD1 was the primary endpoint (PFS1); secondary efficacy endpoints were OS, overall PFS (PFS2) and PFS3 (time from PD1 to PD after crossover, i.e. PD2) and best overall response rates (BORRs).The final analysis (median follow-up 57.0 months, interquartile range 22.7-63.0 months) confirmed longer PFS1 for continuous TT [arm A (69 patients) versus arm B (early switch, 66 patients); hazard ratio (HR) 0.61, 95
%K crossover design (Other)
%K immunotherapy (Other)
%K melanoma (Other)
%K sequential therapy (Other)
%K targeted therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40345056
%R 10.1016/j.esmoop.2025.105053
%U https://inrepo02.dkfz.de/record/301264